Indications
Teizeild is indicated to delay the onset of stage 3 type 1 diabetes (T1D) in adult and paediatric patients 8 years of age and older with stage 2 T1D.
Composition
- Active substance
- teplizumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Teizeild
- Active substance
- teplizumab
- ATC code
- A10XX01
- Therapeutic area
- Diabetes Mellitus, Type 1
- Marketing authorisation holder
- Sanofi Winthrop Industrie
- Status
- Authorised
- EU authorisation
- 8 Jan 2026